RxDoctor Payments Data

Seema Nambiar, MD

Pain Medicine · Plainview, NYNPI 1912985656

Payments from drug & device makers

$9,351in general payments, 2019–2025

Across 479 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Scilex Pharmaceuticals Inc.$1K
  • IBSA Pharma Inc.$409
  • Collegium Pharmaceutical, Inc.$407
  • Pfizer$373
  • Forte Bio-pharma LLC$306
  • plus $3K from 49 others

What the payments were for

  • Food & beverage$9,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)210$3,676
Scilex Pharmaceuticals Inc.53$1,026
IBSA Pharma Inc.14$409
Collegium Pharmaceutical, Inc.24$407
Pfizer21$373
Forte Bio-pharma LLC7$306
Vertex7$273
Virtus Pharmaceuticals LLC16$230
Catalyst Pharmaceuticals, Inc.4$206
Amgen(2 entities)11$206
Lundbeck LLC11$164
Argenx US, Inc.6$156
Harmony Biosciences LLC5$125
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$99
Amneal Pharmaceuticals LLC4$96
Protega Pharmaceutials Inc5$92
Takeda Pharmaceuticals U.S.A., Inc.4$88
GRT US Holding, Inc.4$84
Grifols USA, LLC4$81
Sanofi4$79
Zyla Life Sciences, Inc.4$75
Valinor Pharma, LLC3$65
Neurocrine Biosciences, Inc.2$63
Eisai Inc.3$60
Daiichi Sankyo Inc.3$58
Merz Pharmaceuticals, LLC2$55
UCB, Inc.2$51
Biohaven Pharmaceutical Holding Company Ltd.2$51
AstraZeneca(2 entities)3$48
Boston Scientific2$48
Assertio Therapeutics, Inc.3$48
EMD Serono, Inc.2$44
Indivior Inc.2$36
Biogen2$35
Sunovion Pharmaceuticals Inc.2$32
Biohaven Pharmaceuticals, Inc.1$30
Redhill Biopharma Inc.2$26
Sentynl Therapeutics, Inc.2$26
Merz North America, Inc.1$25
Lilly USA, LLC1$25
SK Life Science, Inc.1$24
Avanir Pharmaceuticals, Inc.1$24
Amylyx Pharmaceuticals, Inc.1$24
Jazz Pharmaceuticals Inc.1$21
Johnson & Johnson1$19
Adamas Pharmaceuticals, Inc.1$18
Arbor Pharmaceuticals, Inc.1$18
Shionogi Inc1$17
Octapharma USA, Inc.1$17
Currax Pharmaceuticals LLC1$17
Biodelivery Sciences International, Inc.1$16
Kowa Pharmaceuticals America, Inc.1$16
Teva Pharmaceuticals USA, Inc.1$15
Azurity Pharmaceuticals, Inc.1$14
Almatica Pharma LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,351 in reported general payments places this provider in the 80th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$40,052
Medicare patients
68
Services billed
2,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl12$22,319
QuliptaAtogepant20$19,931
MovantikNaloxegol Oxalate12$4,776
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen69$1,588
Oxycodone Hcl57$1,187
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$710
Gabapentin66$655
Pregabalin21$636
Duloxetine Hcl39$546
Celecoxib12$248
Morphine Sulfate ErMorphine Sulfate13$209
Baclofen17$193
Tizanidine Hcl17$144
Amitriptyline Hcl15$138
Cyclobenzaprine Hcl26$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$407$22,31912 claims
AbbVieQulipta$3,676$19,93120 claims
Redhill Biopharma Inc.Movantik$26$4,77612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 503 pain medicine providers in New York.

Other pain medicine in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →